Published Paper Details:

Extended release dosage forms cover a wide range of prolonged action preparations that provide continuous release of their active ingredients for a specific period of time. Labetalol used for the treatment of hypertension. The extended release matrix tablets of Labetalol HCl utilize release retarding ability of Eudragit RSPO and Lubritab in different ratios polymers to extend the release of drug over 12 hrs period thereby improve its bioavailability. The tablets were prepared by using wet granulation method.. Extended release matrix tablet of Labetalol HCl were formulated by using different ratios (1:0.5, 1:0.3, 1:0.2, 1:0.1) of polymers. The formulated granules blends were evaluated for angle of repose, tapped density, bulk density and compressibility index. The formulated tablets were subjected to thickness, weight variation test, hardness test, friability test and assay and all parameters are within the limits. In-vitro dissolution studies were carried out by using USP dissolution apparatus Type 2 (paddle type), first 2 hrs in water as a media at 50 rpm for a total period of 12 hrs. Based on the dissolution data comparision with innovator product, among 8 formulations the F7 formulation was found to be optimized formulation. The drug release of formulation F7 followed first order and higuchi kinetics and the mechanism was found to be Fickian diffusion.